Security key
75955J402
RELMADA THERAPEUTICS, INC. - Common Stock (RLMD)
CUSIP: 75955J402
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 1,397,791
- Total 13F value
- $9,672,715
- Share change
- +844,700
- SEC-reported price per share
- $6.92
- Number of holders
- 17
- Value change
- +$5,845,198
- Number of buys
- 11
- Number of sells
- 2
- Shares outstanding
- 105,041,614
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
17
Top holders
10
RLMD full security history
Ownership snapshot
Full 13F holder table
RELMADA THERAPEUTICS, INC. SEC filings
RELMADA THERAPEUTICS, INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of RLMD - RELMADA THERAPEUTICS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
Janus Henderson Group Ltd.
Comparable rows
15/15
Latest evidence
30 Jun 2026
13F
13D/G
Lead comparable stake: 10%
13D/G row: Janus Henderson Group Ltd.
Showing 1-6 of 15 holder rows.
Quick read
Janus Henderson Group Ltd. leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership
Top 5
Janus Henderson Group Ltd.
10%
Squadron Capital Management LLC
9.9%
BlackRock, Inc.
7%
Venrock Healthcare Capital Partne...
6.2%
Spruce Street Capital LP
5.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Janus Henderson Group Ltd. |
13F
13D/G
Company · JANUS HENDERSON GROUP PLC
|
10%
from 13D/G
|
$76,892,206
11,063,862 shares
|
— | 31 Mar 2026 |
| Squadron Capital Management LLC |
13F
13D/G
Company · Squadron Master Fund LP
|
9.9%
from 13D/G
|
$58,983,014
8,474,571 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13D/G
13F
Company
|
7%
|
$50,882,158
7,352,913 shares
|
$0 | 30 Jun 2026 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
6.2%
|
$46,925,802
6,508,433 shares
|
$0 | 02 Jun 2026 |
| Spruce Street Capital LP |
13F
13D/G
Company
|
5.6%
from 13D/G
|
$42,998,208
6,262,114 shares
|
— | 31 Mar 2026 |
| Commodore Capital LP |
13D/G
13F
Company
|
5.1%
|
$40,630,789
5,505,527 shares
|
$0 | 27 Apr 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
17
Shares
1,397,791
Rows available
17
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
102
Q2 2026 holders
17
Holder diff
-85
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|